Edwards syndrome

JUNO DIAGNOSTICS™ EXPANDS ITS PRODUCT PORTFOLIO WITH THE LAUNCH OF JUNO HAZEL™ PLUS AND ANNOUNCES EARLY ACCESS PROGRAM (EAP) FOR INNOVATIVE NIPS TESTS

Retrieved on: 
Monday, January 9, 2023
Klinefelter syndrome, Turner syndrome, Blood, XYY syndrome, Commercial Operating System (COS), Prenatal care, Genetic testing, SAN, Phlebotomy, EAP, XXY, Pregnancy, Patient, Hazel, Edwards, Special access program, Physician, NIPT, XYY, NIPS, Trisomy, Down syndrome, Edwards syndrome, Genetic counseling, Juno, Pharmaceutical industry

Similar to the Juno Hazel™ screening test, Juno Hazel™ Plus leverages JunoDx's proprietary Sample Collection Kit to improve early access to high-quality genetic testing without the high costs, long lead times, and phlebotomy requirements of venous-based NIPS.

Key Points: 
  • Similar to the Juno Hazel™ screening test, Juno Hazel™ Plus leverages JunoDx's proprietary Sample Collection Kit to improve early access to high-quality genetic testing without the high costs, long lead times, and phlebotomy requirements of venous-based NIPS.
  • Juno Hazel™ Plus offers a comprehensive prenatal screening solution by screening for common chromosomal trisomies, sex chromosome aneuploidies, and fetal sex.
  • "The expansion of our product portfolio with the launch of our second NIPS test , Juno Hazel™ Plus, represents a significant milestone for JunoDx™.
  • To ensure every pregnancy has the opportunity to benefit from our product portfolio, the time is now to create and launch a formalized Early Access Program.

Global Non-Invasive Prenatal Testing Market 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, December 23, 2022
Baby, Maternity, Health, Consumer, Medical Devices, Spina bifida, Turner syndrome, Patau syndrome, COVID-19, DNA, Fertility, Development, Risk, Miscarriage, Disease, Pregnancy, Anti-transglutaminase antibodies, Maternal death, CVS, Health care, Chromosome, Cleft lip and cleft palate, NIPT, Parent, Fetus, Down syndrome, Edwards syndrome, Prevalence, Medical imaging, Vaccine

Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman's blood sample to detect the presence of fetal abnormalities.

Key Points: 
  • Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman's blood sample to detect the presence of fetal abnormalities.
  • The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth.
  • Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market.
  • The publisher provides an analysis of the key trends in each sub-segment of the global non-invasive prenatal testing market, along with forecasts at the global, regional and country level from 2022-2027.

UAE In-Vitro Fertilization Market: Growing Medical Tourism for Fertility Treatments Drives Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 11, 2022
Health, Biotechnology, Lists of diseases, Physician, Edwards syndrome, Female, Infertility, Cholesterol, Vitamin D, Woman, Attention, Uterus, Family, Parent, CAGR, ART, Burqa, Chromosome, Obesity, Genetic disorder, AMH, Industry, NGS, Forecast, CCS, Application, Competition, Down syndrome, Awareness, Instrument, IVF, Reagent, Pregnancy, USD, Hormone, Medical device, Mineral oil, Tourism, Birth control

UAE In-Vitro Fertilization (IVF) market stood at USD 231.57 Million in 2021 and is expected to reach a CAGR of 9.64% during the forecast period.

Key Points: 
  • UAE In-Vitro Fertilization (IVF) market stood at USD 231.57 Million in 2021 and is expected to reach a CAGR of 9.64% during the forecast period.
  • UAE offers world class fertility treatment amalgamated with several other amenities such as gynecology consultation, diagnostic tests, etc.
  • As a result of which, most women in UAE face fertility issues because of deteriorated egg number and egg quality.
  • UAE In-Vitro Fertilization (IVF) Market, By Technique:
    UAE In-Vitro Fertilization (IVF) Market, By Reagent:

Premier Medical Laboratory Services Now Offering Noninvasive Prenatal Testing

Retrieved on: 
Wednesday, May 18, 2022
Cancer, Diabetes, Risk, DNA, NGS, Blood, Sex, COLA, Toxicology, Degenerative disease, Amniocentesis, CVS, Placenta, Edwards syndrome, Doctor of Philosophy, Multimedia, Patient, Woman, Down syndrome, Amniotic fluid, Insurance, Health, Edwards, Greenville Triumph SC, Method, Research, Whole genome sequencing, Industry, Aneuploidy, NIPT, Nucleic acid thermodynamics, 2020 Greenville Triumph SC season, Chromosome, Pregnancy, Chorionic villus sampling, CLIA, Trisomy, CEO, Medical imaging

GREENVILLE, S.C., May 18, 2022 /PRNewswire/ -- Premier Medical Laboratory Services (PMLS) is announcing today that they have added Noninvasive Prenatal Testing (NIPT) to their full line of medical diagnostic testing and risk screening services.

Key Points: 
  • GREENVILLE, S.C., May 18, 2022 /PRNewswire/ -- Premier Medical Laboratory Services (PMLS) is announcing today that they have added Noninvasive Prenatal Testing (NIPT) to their full line of medical diagnostic testing and risk screening services.
  • As a laboratory, PMLS strives to offer only the most advanced and accurate testing and screening available for optimal patient care.
  • Premier Medical Laboratory Services (PMLS), headquartered in Greenville, South Carolina, is the official health and wellness partner of the Greenville Triumph and an advanced molecular diagnostics lab fully certified by top laboratory accrediting organizations, including CLIA and COLA.
  • Their expansive menuof highly advanced tests and screenings include genomic risk assessment assays for various cancers, heart disease, and diabetes, as well as women's health panels, toxicology, allergy testing, pharmacogenomics, routine blood chemistry, and noninvasive prenatal testing (NIPT).

QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations

Retrieved on: 
Friday, January 7, 2022
Software, Research, Oncology, Consumer, Technology, Infectious Diseases, Genetics, Science, Baby, Maternity, Nanotechnology, Biotechnology, Health, Other Science, Knowledge, Blood, Severe acute respiratory syndrome coronavirus 2, QGEN, Fetus, Edwards syndrome, Growth, Research, Amniocentesis, PCR, PICO, NYSE, Proteomics, DNA, Life, U.S. Securities and Exchange Commission, Protein, Automation, Disorder, Disease, Trisomy, SEC, Down syndrome, Gene, Bacteria, Biomarker, Senior, Virus, Partnership, Molecular diagnostics, Patau syndrome, RNA, Genomics, Technology, Polymerase, Chromosome, Solution, QIAGEN, Budget, NIPT, Medical imaging, Vaccine, Fine chemical, Insight, Pharma, Academy

QIAGEN has entered into two new collaborations that extend the QIAcuity ecosystem:

Key Points: 
  • QIAGEN has entered into two new collaborations that extend the QIAcuity ecosystem:
    A collaboration with Atila BioSystems to provide non-invasive prenatal testing (NIPT) solutions to QIAGENs dPCR franchise.
  • QIAcuity is expanding into new research fields as a cost-effective and very reliable digital PCR system, said Thomas Schweins, Senior Vice President, Head of the Life Science Business Area at QIAGEN.
  • Our aim is to make digital PCR and QIAcuity the new standard in PCR.
  • We expect more than half of all traditional PCR applications to eventually move to digital PCR.

Outlook on the Non-Invasive Prenatal Testing Global Market to 2026 - by Product Type, Test Type, Technology, Method, Application, End-user and Region

Retrieved on: 
Wednesday, August 25, 2021
Patau syndrome, CAGR, Down syndrome, Health care, Agilent Technologies, Lists of diseases, Genomics, Chromosome, Turner syndrome, Thermo Fisher Scientific, Fertility, DNA, CVS, Disease, Prevalence, Pregnancy, Illumina, Inc., Awareness, Maternal death, NIPT, Fetus, Risk, PerkinElmer, GE Healthcare, Spina bifida, Cleft lip and cleft palate, Edwards syndrome, Miscarriage, Development, Anti-transglutaminase antibodies, Parent, Medical imaging

DUBLIN, Aug. 25, 2021 /PRNewswire/ -- The "Non-Invasive Prenatal Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 25, 2021 /PRNewswire/ -- The "Non-Invasive Prenatal Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global non-invasive prenatal testing market exhibited strong growth during 2015-2020.
  • Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman's blood sample to detect the presence of fetal abnormalities.
  • Looking forward, the publisher expects the global non-invasive prenatal testing market to grow at a CAGR of 10.70% during 2021-2026.

Worldwide Non-Invasive Prenatal Testing Industry to 2026 - Featuring GE Healthcare, Illumina and Perkinelmer Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 25, 2021
Medical Devices, Health, Patau syndrome, Down syndrome, CAGR, Health care, Lists of diseases, Chromosome, Turner syndrome, Fertility, DNA, CVS, Disease, Prevalence, Pregnancy, Awareness, Maternal death, NIPT, Risk, Spina bifida, Cleft lip and cleft palate, Edwards syndrome, Miscarriage, Development, Anti-transglutaminase antibodies, Fetus, Parent, Medical imaging

The "Non-Invasive Prenatal Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Invasive Prenatal Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global non-invasive prenatal testing market exhibited strong growth during 2015-2020.
  • Looking forward, the publisher expects the global non-invasive prenatal testing market to grow at a CAGR of 10.70% during 2021-2026.
  • Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman's blood sample to detect the presence of fetal abnormalities.